Prostate Cancer with PTEN Deficiency — An Interview with Dr Neeraj Agarwal

Featuring an interview with Dr Neeraj Agarwal, including the following topics:

• Impact of PTEN deficiency on PI3K/AKT/mTOR pathway; optimal approaches to testing (0:00)
• Approaches to monitoring for disease progression in patients who are PTEN deficient; prognostic significance and implications for testing (7:13)
• Potential usage of capivasertib as second-line therapy for metastatic androgen pathway modulation-naïve/-sensitive (APMN/S) prostate cancer (15:15)
• Managing treatment-related adverse events from capivasertib (20:08)
• Case: A man in his late 50s diagnosed with metastatic APMS prostate cancer and a PTEN deficiency who receives capivasertib (29:17)
• Case: A man in his late 70s diagnosed with high-volume metastatic APMN prostate cancer and a PTEN deficiency who experiences disease progression on androgen deprivation therapy and enzalutamide (40:39)

CME information and select publications